Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies

Donalson, Kim; Turner, Steve; Wastell, H.; Cuckle, Howard

doi:10.1002/pd.2043

Cited by 10 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protein is both highly expressed in placenta and extracellular, but failed the criteria used in the textmining step. It should be noted, however, that most recent studies find this biomarker to be informative only before 10 weeks of gestation, so the applicability of this protein is already limited [34]–[38]. The finding that two complementary textmining methods did not find sufficient evidence for association of ADAM12 with trophoblasts can either indicate that current literature databases only provide weak evidence for this association, or that both textmining tools were not successful in detecting an existing association.…”

Section: Discussionmentioning

confidence: 98%

Discovery of Novel Serum Biomarkers for Prenatal Down Syndrome Screening by Integrative Data Mining

et al. 2009

View full text Add to dashboard Cite

BackgroundTo facilitate the experimental search for novel maternal serum biomarkers in prenatal Down Syndrome screening, we aimed to create a set of candidate biomarkers using a data mining approach.Methodology/Principal FindingsBecause current screening markers are derived from either fetal liver or placental trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues. By applying a three-stage filtering strategy on publicly available data from different sources, we identified 49 potential blood-detectable protein biomarkers. Our set contains three biomarkers that are currently widely used in either first- or second-trimester screening (AFP, PAPP-A and fβ-hCG), as well as ten other proteins that are or have been examined as prenatal serum markers. This supports the effectiveness of our strategy and indicates the set contains other markers potentially applicable for screening.Conclusions/SignificanceWe anticipate the set will help support further experimental studies for the identification of new Down Syndrome screening markers in maternal blood.

show abstract

Section: Discussionmentioning

confidence: 98%

Discovery of Novel Serum Biomarkers for Prenatal Down Syndrome Screening by Integrative Data Mining

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Later studies, using a new DELFIA platform (PerkinElmer Life Sciences, Turku, Finland), supported these early results, placing the discriminatory power of ADAM-12 greatest prior to 10 weeks' gestation [21][22][23][24][25] . In the second trimester, ADAM-12 levels were found to be increased in trisomy-21 pregnancies [26,27] .…”

Section: Adam-12 In Adverse Pregnancy Outcomesmentioning

confidence: 99%

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Matwejew

Cowans²,

Stamatopoulou³

et al. 2010

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: To investigate first-trimester ADAM-12 levels in pregnancies which later develop hypertensive and growth complications. Methods: First-trimester serum samples (11⁺⁰ to 13⁺⁶ weeks) were retrieved from frozen storage. 47 samples with at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age, HELLP syndrome and gestational hypertension were analysed and 452 controls matched to the cases by gestational age and length of storage were analysed. ADAM-12 levels were measured by the automated AutoDELFIA immunoassay platform. Results: ADAM-12 was found to increase with gestational age (11⁺⁰ to 13⁺⁶ weeks) and decrease with increasing maternal weight and in women who smoked. After correction, ADAM-12 median multiples of the median were increased in cases with HELLP syndrome, all PE and PE only. Conclusion: The increased first-trimester levels of ADAM-12 in PE and HELLP are in contrast with previous findings. The usefulness of ADAM-12 as a marker for adverse outcomes is still unclear.

show abstract

Maternal Serum Screening for Chromosomal Abnormalities and Neural Tube Defects

Cuckle

Pergament

Benn

2015

Genetic Disorders and the Fetus

View full text Add to dashboard Cite

Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies

Abstract: ADAM12 is a second trimester marker of Down's syndrome, with discriminatory power similar to existing markers. It could be considered in multi-marker combinations.

Cited by 10 publications

References 10 publications

Discovery of Novel Serum Biomarkers for Prenatal Down Syndrome Screening by Integrative Data Mining

Discovery of Novel Serum Biomarkers for Prenatal Down Syndrome Screening by Integrative Data Mining

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Maternal Serum Screening for Chromosomal Abnormalities and Neural Tube Defects

Contact Info

Product

Resources

About